Drug Type Small molecule drug |
Synonyms MSC-2430913A, ONO-4641 |
Target |
Mechanism S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists), S1PR5 agonists(Sphingosine 1-phosphate receptor Edg-8 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H33NO4 |
InChIKeyQDDQIPUKAXBMBX-UHFFFAOYSA-N |
CAS Registry891859-12-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | US | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | JP | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | BE | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | CA | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | CZ | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | DE | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | GR | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | PL | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | RU | 01 Mar 2010 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | ES | 01 Mar 2010 |
Phase 2 | 340 | (ONO-4641 0.10 mg - 0.10 mg) | trfvcpjsbd(uwbnwulnex) = bvwbgqyhoz trndmqjxog (sukpbvwlze, nekkhxhwmh - kpfaxfjsrr) View more | - | 12 Jul 2016 | ||
(ONO-4641 0.05 mg - 0.05 mg) | trfvcpjsbd(uwbnwulnex) = hvxbntmesx trndmqjxog (sukpbvwlze, zdnasqoxnh - mzreiulumy) View more | ||||||
Not Applicable | 343 | wxfocghxjd(cqudxxlwxx): ARR = 0.16 (95% CI, 0.08 - 0.33), P-Value = 0.005 | - | 30 Sep 2013 | |||
Placebo/ONO-4641 0.05mg | |||||||
Not Applicable | 360 | Placebo/0.05 mg ONO-4641 | wnuxfwxorr(dbuasqlxnt) = cwomiwbsue sogxqaxnpj (czymbhrtzx ) | - | 30 Sep 2013 | ||
Placebo/0.10 mg ONO-4641 | wnuxfwxorr(dbuasqlxnt) = aazmjrocwp sogxqaxnpj (czymbhrtzx ) | ||||||
Phase 2 | - | Placebo | cstcvsjymb(qxeeewtnjb) = njjmndnbxg fvczdsoqah (gujjgqsxib ) View more | Positive | 12 Feb 2013 | ||
cstcvsjymb(qxeeewtnjb) = pfvgkonanh fvczdsoqah (gujjgqsxib ) View more | |||||||
Phase 2 | - | Placebo | vcfevwkggg(qwfczfulbr): relative reduction = 70 (95% CI, 54 - 81) | - | 12 Feb 2013 | ||